Compare GTLB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GTLB | DFTX |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2021 | 2020 |
| Metric | GTLB | DFTX |
|---|---|---|
| Price | $41.67 | $44.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 27 | 8 |
| Target Price | $37.17 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 4.1M | 2.1M |
| Earning Date | 06-09-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,224,000.00 | N/A |
| Revenue This Year | $18.72 | N/A |
| Revenue Next Year | $16.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.81 | N/A |
| 52 Week Low | $18.73 | $14.62 |
| 52 Week High | $52.38 | $49.70 |
| Indicator | GTLB | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 55.05 |
| Support Level | $36.50 | $40.46 |
| Resistance Level | $43.00 | $45.42 |
| Average True Range (ATR) | 1.97 | 2.76 |
| MACD | 0.07 | -0.07 |
| Stochastic Oscillator | 74.65 | 49.56 |
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.